The Itch - How Dupilumab Reduces Mucus Burden in Asthma - VESTIGE Trial
This episode was created in collaboration with, and first posted on, The Itch podcast.
Mucus plugging is a challenge in asthma care. It’s thick, sticky mucus that blocks the airways and doesn’t respond to regular inhalers. Even when inflammation improves, these plugs can lower lung function, limit how well medicine works, and make asthma harder to control.
In this episode, The Itch breaks down the study: “Effect of Dupilumab on Mucus Burden in Patients with Moderate-to-Severe Asthma,” published Oct. 28, 2025. The analysis looks at whether dupilumab (Dupixent), a biologic that blocks IL-4 and IL-13, can lower mucus burden and improve lung function, especially in people who start with a high “mucus plug score.”
Read the paper: https://www.atsjournals.org/doi/abs/10.1164/rccm.202410-1894OC
Mucus plugging is a challenge in asthma care. It’s thick, sticky mucus that blocks the airways and doesn’t respond to regular inhalers. Even when inflammation improves, these plugs can lower lung function, limit how well medicine works, and make asthma harder to control.
In this episode, The Itch breaks down the study: “Effect of Dupilumab on Mucus Burden in Patients with Moderate-to-Severe Asthma,” published Oct. 28, 2025. The analysis looks at whether dupilumab (Dupixent), a biologic that blocks IL-4 and IL-13, can lower mucus burden and improve lung function, especially in people who start with a high “mucus plug score.”
Read the paper: https://www.atsjournals.org/doi/abs/10.1164/rccm.202410-1894OC